William Tillett1, Lihi Eder1, Niti Goel1, Maarten De Wit1, Dafna D Gladman1, Oliver FitzGerald1, Willemina Campbell1, Philip S Helliwell1, Laure Gossec1, Ana-Maria Orbai1, Alexis Ogdie1, Vibeke Strand1, Neil J McHugh1, Philip J Mease1. 1. From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Abstract
OBJECTIVE: To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework. METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting. RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity." CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.
OBJECTIVE: To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework. METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting. RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity." CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.
Authors: Philip Mease; Ernest Choy; Peter Nash; Chrysostomos Kalyvas; Matthias Hunger; Luminita Pricop; Kunal K Gandhi; Steffen M Jugl; Howard Thom Journal: Eur J Rheumatol Date: 2018-07-01
Authors: Alexis Ogdie; Maarten de Wit; Kristina Callis Duffin; Willemina Campbell; Jeffrey Chau; Laura C Coates; Lihi Eder; Musaab Elmamoun; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Jana James; Umut Kalyoncu; John Latella; Chris Lindsay; Philip J Mease; Denis O'Sullivan; Ingrid Steinkoenig; Vibeke Strand; William Tillett; Ana-Maria Orbai Journal: J Rheumatol Date: 2017-05 Impact factor: 4.666
Authors: Andrew J K Ostor; Ahmed M Soliman; Kim A Papp; Byron Padilla; Zailong Wang; Ann Eldred; Kurt de Vlam; Alan Kivitz Journal: RMD Open Date: 2022-06
Authors: Ana-Maria Orbai; Philip J Mease; Maarten de Wit; Umut Kalyoncu; Willemina Campbell; William Tillett; Lihi Eder; Musaab Elmamoun; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Chris A Lindsay; Ingrid Steinkoenig; Philip S Helliwell; Neil J McHugh; Vibeke Strand; Alexis Ogdie Journal: J Rheumatol Date: 2016-05 Impact factor: 4.666
Authors: Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl Journal: Rheumatol Ther Date: 2018-03-31
Authors: Umut Kalyoncu; Alexis Ogdie; Willemina Campbell; Clifton O Bingham; Maarten de Wit; Dafna D Gladman; Philip Mease; Ingrid Steinkoenig; Vibeke Strand; Victoria G Riese; Ana-Maria Orbai Journal: RMD Open Date: 2016-03-03
Authors: Piet van Riel; Rieke Alten; Bernard Combe; Diana Abdulganieva; Paola Bousquet; Molly Courtenay; Cinzia Curiale; Antonio Gómez-Centeno; Glenn Haugeberg; Burkhard Leeb; Kari Puolakka; Angelo Ravelli; Bernhard Rintelen; Piercarlo Sarzi-Puttini Journal: RMD Open Date: 2016-11-24
Authors: Ana-Maria Orbai; Maarten de Wit; Philip J Mease; Kristina Callis Duffin; Musaab Elmamoun; William Tillett; Willemina Campbell; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Pil Hoejgaard; Ying Ying Leung; Chris Lindsay; Vibeke Strand; Désirée M van der Heijde; Bev Shea; Robin Christensen; Laura Coates; Lihi Eder; Neil McHugh; Umut Kalyoncu; Ingrid Steinkoenig; Alexis Ogdie Journal: J Rheumatol Date: 2017-02-01 Impact factor: 4.666